🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Innovative Ovarian Cancer Biomarker Assays

Recruitingn/aAges 35 Years - anyFemaleNational and Kapodistrian University of Athens
NCT07693894 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes. Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care. The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer. The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer. This study is for research purposes only. The blood-based tests being ev

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: EOC patients 1. Women, trans men and non-binary people with female reproductive organs 2. Aged ≥35 years\* 3. Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment 4. Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC) 5. Able to give informed consent Healthy controls 1. Women, trans men and non-binary people with female reproductive organs 2. Aged ≥35 years 3. No cancer history 4. Able to give informed consent Exclusion Criteria: 1. Prior history and any treatment for malignancy 2. Prior removal of either ovary for any reason 3. Pregnant or lactating 4. Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements
💊

What it tests

  • Investigational ovarian cancer biomarker assays
📍

Where

7 sites
Vseobecna Fakultni Nemocnice V Praze
Prague, Czechia
Fakultni Nemocnice Bulovka
Prague, Czechia
National Centre for Scientific Research Demokritos
Athens, Greece
Dept of Clinical Therapeutics, Alexandra Hospital
Athens, Greece
Lithuanian University of Health Sciences
Kaunas, Lithuania
Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E.
Lisbon, Portugal
Imperial College Healthcare NHS Trust Hammersmith Hospital
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy